Canada Markets closed

Adamas Pharmaceuticals, Inc. (ADMS)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
8.17-0.03 (-0.37%)
At close: 04:00PM EST

Adamas Pharmaceuticals, Inc.

1900 Powell Street
Suite 1000
EmeryVille, CA 94608
United States
510 450 3500
http://www.adamaspharma.com

Sector(s)Healthcare
IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees138

Key Executives

NameTitlePayExercisedYear Born
Mr. Neil F. McFarlaneCEO & Director1.26MN/A1973
Mr. Christopher B. PrentissChief Financial Officer597.58kN/A1975
Mr. Vijay Shreedhar Ph.D.Chief Commercial Officer722.83kN/A1971
Ms. Sarah MathiesonHead of Corp. Communications, Patient Advocacy & EngagementN/AN/AN/A
Dr. Jill M. JeneHead of Corp. Devel., Strategy , Portfolio Planning & Alliance ManagementN/AN/A1973
Mr. Eric C. SchlezingerHead of HRN/AN/A1967
Mr. Adrian Quartel M.D.Chief Medical OfficerN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States. It offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, as well as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing OFF episodes; and OSMOLEX ER, an extended release tablet to treat Parkinson's disease and drug-induced extrapyramidal reactions in adult patients. The company is also developing ADS-4101, which has completed two Phase 1b studies for treating partial onset seizures in patients with epilepsy. In addition, it offers NAMZARIC and NAMENDA XR, a memantine hydrochloride extended release and donepezil hydrochloride capsules for the treatment of moderate to severe dementia of an Alzheimer's type. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.

Corporate Governance

Adamas Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.